title: Survival without biliary complications after liver transplant for primary sclerosing cholangitis.
abstract: OBJECTIVE
  Patients who have a liver transplant for primary sclerosing cholangitis may develop recurrent disease and biliary complications, organ loss necessitating revision liver transplant, or death. We evaluated long-term outcomes in patients who had liver transplant for primary sclerosing cholangitis.
  
  
  METHODS
  In 71 patients who had a liver transplant for end-stage liver disease because of primary sclerosing cholangitis, a retrospective review was done to evaluate biliary complication-free survival, transplanted organ survival, and death. Human leukocyte antigen typing and matching were reviewed.
  
  
  RESULTS
  There were 39 patients (55%) who had biliary complications, loss of the liver transplant, or death at a mean 12.1 years after transplant. The 5- and 10-year event-free survival reached 74.6% and 45% (53 patients after 5 years, and 32 patients after 10 years). Male sex of transplant recipients was a significant risk factor for biliary complications, revision liver transplant, or death. Most patients had inflammatory bowel disease, primarily ulcerative colitis. The human leukocyte antigen profile or number of mismatches had no effect on complication-free survival.
  
  
  CONCLUSIONS
  Biliary complications, revision liver transplant, and death are a useful combined primary endpoint for recurrent primary sclerosing cholangitis after liver transplant.
authors.affiliation: Department of General, Visceral and Transplantation Surgery, Charité-Universitätsmedizin Berlin, Berlin, Germany.
authors.forename: Martina T
authors.initials: MT
authors.lastname: Mogl
authors.forename: Kathrin
authors.initials: K
authors.lastname: Albert
authors.forename: Andreas
authors.initials: A
authors.lastname: Pascher
authors.forename: Igor
authors.initials: I
authors.lastname: Sauer
authors.forename: Gero
authors.initials: G
authors.lastname: Puhl
authors.forename: Safak
authors.initials: S
authors.lastname: Gül
authors.forename: Constanze
authors.initials: C
authors.lastname: Schönemann
authors.forename: Peter
authors.initials: P
authors.lastname: Neuhaus
authors.forename: Olaf
authors.initials: O
authors.lastname: Guckelberger
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001660:Biliary Tract Diseases / Q000453:epidemiology*; D015209:Cholangitis, Sclerosing / Q000401:mortality* / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology*; D006680:HLA Antigens; D006801:Humans; D015994:Incidence; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D012737:Sex Factors; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D006680:HLA Antigens